Journal of the American Academy of Dermatology · 2013
Compliance with pregnancy prevention measures during isotretinoin therapy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Collins Mary-Katharine, Moreau Jacqueline F, Opel Dan, Swan James, Prevost Noel, Hastings Matthew, Bimla Schwarz Eleanor, Korb Ferris Laura
Аннотация
BACKGROUND: Approximately 150 women annually become pregnant while taking isotretinoin despite participation in the iPLEDGE program. Noncompliance with the requirement to be abstinent or use 2 contraceptive methods may be a contributing factor.
OBJECTIVE: We sought to determine the degree of adherence to contraception or abstinence among women taking isotretinoin.
METHODS: We conducted an anonymous survey of women of childbearing potential taking isotretinoin for at least 2 months.
RESULTS: Among 75 participants, 21 (28%) chose abstinence as their primary means of pregnancy prevention, of whom 4 (19%) were sexually active during treatment. The most commonly chosen contraceptive methods among the 39 women who were sexually active were condoms (35, 90%) and oral contraceptive pills (18, 46%). Twelve women (31%) admitted to having intercourse at least once using 1 or fewer forms of contraception; 10 failed to use condoms, and 1 reported completely unprotected intercourse. Among sexually active oral contraceptive pill users, 7 (39%) reported missing 1 or more pills in the previous month.
LIMITATIONS: Data were self-reported, thus participants may have inaccurately reported contraception use.
CONCLUSIONS: Encouraging the use of highly effective, patient-independent contraception and limiting abstinence to women who have never been sexually active may further reduce the rate of isotretinoin-exposed pregnancies.
OBJECTIVE: We sought to determine the degree of adherence to contraception or abstinence among women taking isotretinoin.
METHODS: We conducted an anonymous survey of women of childbearing potential taking isotretinoin for at least 2 months.
RESULTS: Among 75 participants, 21 (28%) chose abstinence as their primary means of pregnancy prevention, of whom 4 (19%) were sexually active during treatment. The most commonly chosen contraceptive methods among the 39 women who were sexually active were condoms (35, 90%) and oral contraceptive pills (18, 46%). Twelve women (31%) admitted to having intercourse at least once using 1 or fewer forms of contraception; 10 failed to use condoms, and 1 reported completely unprotected intercourse. Among sexually active oral contraceptive pill users, 7 (39%) reported missing 1 or more pills in the previous month.
LIMITATIONS: Data were self-reported, thus participants may have inaccurately reported contraception use.
CONCLUSIONS: Encouraging the use of highly effective, patient-independent contraception and limiting abstinence to women who have never been sexually active may further reduce the rate of isotretinoin-exposed pregnancies.